加拿大艾伯塔省口咽鳞状细胞癌的主要治疗方法：一项基于人群的研究。

Primary treatment for oropharyngeal squamous cell carcinoma in Alberta, Canada: A population-based study.

作者信息

Hobbs Amy J, Brockton Nigel T, Matthews T Wayne, Chandarana Shamir P, Bose Pinaki, Guggisberg Kelly, Fick Gordon H, Dort Joseph C

机构信息

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

The Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.

出版信息

Head Neck. 2017 Nov;39(11):2187-2199. doi: 10.1002/hed.24889. Epub 2017 Aug 7.

DOI:10.1002/hed.24889

PMID:28782304

Abstract

BACKGROUND

The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (SCC) is increasing and has better survival than non-HPV related oropharyngeal SCC. This study compared surgical to nonsurgical treatments and demographic, clinical, and survival differences in patients with oropharyngeal SCC, stratified by p16 status.

METHODS

We assembled a cohort of adult patients with oropharyngeal SCC diagnosed between 2000 and 2008 in Alberta. The tumor p16 biomarker was measured using fluorescent immunohistochemistry.

RESULTS

In this cohort, p16 data were available for 115 of 357 patients; and 66% (n = 76) were p16-positive. Patients with p16 data had comparable outcomes to those without. Surgically treated p16-negative patients had improved 5-year disease-specific survival (DSS) and overall survival (OS) compared with nonsurgical patients. There were no differences in survival outcomes between surgical and nonsurgical treatment for patients with p16-positive disease.

CONCLUSION

Patients with p16-positive oropharyngeal SCC had similar outcomes regardless of treatment. Patients with p16-negative tumors may benefit from primary surgery with postoperative adjuvant therapy.

摘要

背景

人乳头瘤病毒（HPV）相关的口咽鳞状细胞癌（SCC）发病率正在上升，且其生存率高于非HPV相关的口咽SCC。本研究比较了口咽SCC患者手术治疗与非手术治疗的效果，以及按p16状态分层的患者在人口统计学、临床和生存方面的差异。

方法

我们收集了2000年至2008年在艾伯塔省诊断为口咽SCC的成年患者队列。使用荧光免疫组织化学方法检测肿瘤p16生物标志物。

结果

在该队列中，357例患者中有115例有p16数据；其中66%（n = 76）为p16阳性。有p16数据的患者与没有p16数据的患者预后相当。与非手术治疗的患者相比，接受手术治疗的p16阴性患者5年疾病特异性生存率（DSS）和总生存率（OS）有所提高。p16阳性疾病患者手术和非手术治疗的生存结果没有差异。